1. Clinical & Scientific Overview
Pentazocine Lactate / Hydrochloride (TIP-MED-000521, Reference Code [R-02]) is classified under
Analgesics & Anaesthetic Adjuncts as a Mixed Opioid Agonist-Antagonist Analgesic.
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 / Psychotropic Substance (NDPS Act, 1985).
Fortwin (Sun Pharmaceutical Industries), Susevin (Neon Laboratories), Pentawin (Biochem Pharmaceutical)
Injection: 30 mg/mL (1 mL ampoule); Oral Tablet: 50 mg
Statutory Restriction, High-Alert & Dispensing Safeguards
Indian Regulatory & Statutory Control Basis: Schedule H1 / Psychotropic Substance (NDPS Act, 1985)
High-Alert Clinical Risk, Dependence & Narrow Therapeutic Index Warnings: High dependence and parenteral abuse liability; causes psychotomimetic dysphoria/hallucinations at high doses, increases pulmonary arterial and systemic blood pressure (avoid in acute MI), and causes fibrous myopathy at repeated IM injection sites.
Mandatory Dispensing Register & Institutional Custody Protocol: Schedule H1 mandatory retention register (patient name, prescriber registration, quantity dispensed); rotate parenteral sites and avoid post-MI use.
3. Mechanism of Action & Pharmacodynamics
Agonist at kappa-opioid receptors (KOR) producing spinal analgesia and sedation, with weak antagonist or partial agonist activity at mu-opioid receptors.
4. Therapeutic Indications & Evidence-Supported Uses
- Moderate-to-severe acute surgical, trauma, or obstetric pain
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Specialist-Supervised Educational Reference Summary: Dosing of Pentazocine must be individualised by a qualified specialist according to clinical indication, organ function, and institutional protocol (Injection: 30 mg/mL (1 mL ampoule); Oral Tablet: 50 mg).
Administration & Meal Timing: Routes: Intramuscular, Subcutaneous, Intravenous, Oral. Schedule H1 mandatory retention register (patient name, prescriber registration, quantity dispensed); rotate parenteral sites and avoid post-MI use.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Exhibits mixed opioid agonist-antagonist analgesic pharmacokinetic disposition; verify baseline renal and hepatic clearance and check for active or prolonged-half-life metabolites before repeat dosing.
Hepatic Phase I (CYP450) and/or Phase II conjugation or specific non-renal clearance as detailed in clinical warnings.
Verify eGFR / CrCl before initiation; see specific metabolite and renal clearance notes above.
Assess baseline Child-Pugh status and hepatic transaminases prior to therapy.
7. Contraindications, Precautions & High-Risk Warnings
- Known severe hypersensitivity to Pentazocine or formulation excipients
- Unsupervised outpatient self-administration or dispensing without mandatory statutory prescription verification
- Specific clinical contraindications detailed under High-Alert Warnings & Statutory Restrictions
Key Clinical Precautions: High dependence and parenteral abuse liability; causes psychotomimetic dysphoria/hallucinations at high doses, increases pulmonary arterial and systemic blood pressure (avoid in acute MI), and causes fibrous myopathy at repeated IM injection sites.
8. Adverse Effects Profile
- High dependence and parenteral abuse liability; causes psychotomimetic dysphoria/hallucinations at high doses, increases pulmonary arterial and systemic blood pressure (avoid in acute MI), and causes fibrous myopathy at repeated IM injection sites.
- Dose-dependent target-organ pharmacodynamic effects requiring clinical observation
- High dependence and parenteral abuse liability; causes psychotomimetic dysphoria/hallucinations at high doses, increases pulmonary arterial and systemic blood pressure (avoid in acute MI), and causes fibrous myopathy at repeated IM injection sites.
- High-alert toxicity, dependence/diversion risk, or severe organ-specific adverse events if administered outside protocol
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- High dependence and parenteral abuse liability; causes psychotomimetic dysphoria/hallucinations at high doses, increases pulmonary arterial and systemic blood pressure (avoid in acute MI), and causes fibrous myopathy at repeated IM injection sites.
- Review all concomitant CNS depressants, QTc-prolonging agents, nephrotoxins, or CYP450 modulators prior to dispensing.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Schedule H1 mandatory retention register (patient name, prescriber registration, quantity dispensed); rotate parenteral sites and avoid post-MI use.
Pharmacist Patient Counselling Points:
- Schedule H1 mandatory retention register (patient name, prescriber registration, quantity dispensed); rotate parenteral sites and avoid post-MI use.
- Must be used strictly under direct medical supervision; never share prescription medicines or alter the prescribed dose.
Storage, Stability & Dispensing Safeguards: Schedule H1 mandatory retention register (patient name, prescriber registration, quantity dispensed); rotate parenteral sites and avoid post-MI use.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Drugs and Cosmetics Act, 1940 & Rules, 1945 (Schedule H / H1 / X); NDPS Act, 1985 & Essential Narcotic Drugs (END) Notification; Indian Pharmacopoeia (IP) & National Formulary of India (NFI).
Official Verification Portals: CDSCO — Drugs & Cosmetics Act and Rules (Schedules H, H1, X) • Department of Revenue — Narcotic Drugs and Psychotropic Substances (NDPS) Act • Indian Pharmacopoeia Commission (IPC) — National Formulary of India
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [R-03] Pethidine Hydrochloride (Meperidine) — Synthetic Phenylpiperidine Mu-Opioid Agonist
- [R-04] Methadone Hydrochloride — Synthetic Long-Acting Mu-Opioid Agonist & NMDA Antagonist
- [R-05] Codeine Phosphate — Phenanthrene Opioid Agonist & Central Antitussive
- [R-01] Buprenorphine (Sublingual & Transdermal) — Partial Mu-Opioid Agonist & Kappa-Opioid Antagonist
